WNK2 and melanoma: Activating mutations in NRAS have been reported in approximately 20% of all melanomas[28] and are potentially sensitive to therapeutics that target downstream signaling through mitogen-activated protein kinase kinase and phosphatidylinositol 3-OH kinase or AKT[29,30].